Silence Therapeutics plc ADR 2026年季度报告

FORM 10-Q QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 ☒ For the quarterly period ended March 31, 2026or ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934For the transition period from ____________ to ____________Commission File Number: 001-39487 Silence Therapeutics plc(Exact name of registrant as specified in its charter) England and WalesNot Applicable(State or other jurisdiction of incorporation or organization)(I.R.S. Employer Identification No.) London, United KingdomW6 7AP(Address of principal executive offices)(Zip Code) +44 20 3457 6900(Registrant’s telephone number, including area code) (Former name, former address and former fiscal year, if changed since last report) Securities registered pursuant to Section 12(b) of the Act: *Not for trading, but only in connection with the listing of the American Depositary Shares on The Nasdaq Stock Market LLC Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject tosuch filing requirements for the past 90 days.☒Yes☐No Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required tosubmit such files).☒Yes☐No Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company,or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and "emerginggrowth company" in Rule 12b-2 of the Exchange Act. Accelerated filer☐Smaller reporting company☒Emerging growth company☐ Large accelerated filer☐Non-accelerated filer☒ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying withany new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.☐ Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).☐Yes☒No As of April 30, 2026, the registrant had 141,703,840 ordinary shares (including ordinary shares in the form of American Depositary Shares)outstanding, nominal value £0.05 per share. SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS This Quarterly Report on Form 10-Q, or Quarterly Report, contains forward-looking statements that involve substantial risksand uncertainties. In some cases, you can identify forward-looking statements by the words “may,” “might,” “will,” “could,”“would,” “should,” “expect,” “intend,” “plan,” “objective,” “anticipate,” “believe,” “estimate,” “predict,” “potential,” “continue”and “ongoing,” or the negative of these terms, or other comparable terminology intended to identify statements about the future.These statements involve known and unknown risks, uncertainties and other important factors that may cause our actual results,levels of activity, performance or achievements to be materially different from the information expressed or implied by theseforward-looking statements. The forward-looking statements and opinions contained in this Quarterly Report are based uponinformation available to us as of the date of this Quarterly Report and, while we believe such information forms a reasonable basisfor such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we haveconducted an exhaustive inquiry into, or review of, all potentially available relevant information. Forward-looking statementsinclude, but are not limited to, statements about: •the development of our product candidates, including statements regarding the timing of initiation, completion and theoutcome of preclinical studies or clinical trials and related preparatory work, the period during which the results of thetrials will become available and our research and development programs;•our ability to obtain and maintain regulatory approval of our product candidates in the indications for which we plan todevelop them, and any related restrictions, limitations or warnings in the label of an approved drug or therapy;•our plans to collaborate, or statements regarding the ongoing collaborations, with third parties;•our plans to research, develop, manufacture and commercialize our product candidates;•the timing of our regulatory filings for our product candidates;•the size and growth potential of the markets for our product candidates;•our ability to raise additional capital;•our commercialization, marketing and manufacturing capabilities and stra